For those with Vitamin B12 deficiency, injections are an effective means of rapidly increasing blood oxygen levels, often in a noticeable boost in energy
Regulators are concerned that making the medicine widely available could lead to: Misdiagnosis: Patients self-treating a different, underlying condition
Over 68 weeks in the REDEFINE trials, cagrilintide 2.4 mg alone achieved approximately 10.8% body weight reduction
The resulting oxidized peptide has altered folding and reduced biological activity
Funding This work was supported by grants from the National Natural Science Foundation of China (NSFC Numbers 81672800, 81603009, 81673020, 81802632, and 82173830), Natural Science Foundation of Shaanxi (2020JQ-445), and the Key Research and Development Program of Shaanxi Province (2021SF-207, 2021SF-223, and 2022ZDLSF05-19)
Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date
